Edgewise Therapeutics, Inc.

Last year was far from vintage for the biotech sector in terms of stock performance: the S&P Biotechnology Select Industry Index rose by only 3% in 2024, and lagged far behind the 25% achieved by

Edgewise Therapeutics has unveiled impressive results from EDG-7500, a novel treatment for the heart condition, obstructive hypertrophic cardiomyopathy (oHCM), with early safety and efficacy data exc

CG Oncology, Inc. achieved what no biopharmaceutical company has been able to do for more than two months – it went public in the US. The bladder cancer drug developer also launched the first initial

Biopharma Financing Biopharma financings during the third quarter of 2022 totaled $18.1bn from 236 deals. The largest was a $1.39bn royalty sale by Theravance Biopharma to Royalty Pharma , which acqu